In medicine, improving prognosis is the ultimate goal of all diagnostic and therapeutic decisions. Prognosis commonly relates to the probability or risk of an individual developing a particular state of health. Health care providers need to make decisions to order tests for 350diagnostic work-up or decisions relating to therapeutics such as starting or delaying treatments, surgical decision-making, and changing or modifying the intensity of treatments. A clinical prediction model (often referred to as the clinical prediction rule, prognostic model, or risk score) is developed to calculate estimates of the probability of the presence/occurrence or future course of a particular patient outcome from multiple clinical or non-clinical predictors in order to help individualize diagnostic and therapeutic decision-making in healthcare practice (1).

For example, the Framingham risk score is well known in public health as a prediction model used to estimate the probability of the occurrence of a cardiovascular disease in an individual within 10 years. It is calculated using traditional risk factors such as age, sex, systolic blood pressure, hypertension treatment, total and high-density lipoprotein cholesterol levels, smoking, and diabetes (2). In clinical practice and medical research, baseline characteristics and laboratory values have been commonly used to predict patient outcome. For instance, risk estimation for the hepatocellular carcinoma in chronic hepatitis B score was developed using sex, age, serum alanine aminotransferase concentration, hepatitis B e antigen status, and serum hepatitis B virus DNA level (3).

In radiology practice and research, diagnostic imaging tests have traditionally been viewed and evaluated by assessing their performance to diagnose a particular target disease state. For example, ultrasound features of thyroid nodules have been used in risk stratification of thyroid nodules (4). Coronary computed tomography (CT) angiography (CCTA) has been evaluated for the selection of coronary artery bypass graft candidates (5). Recently, it appears that imaging findings are also often used as predictive parameters, either for standalone prediction or as an addition to the traditional clinical prediction models. For example, cardiac CT, including coronary artery calcium scoring and CCTA, provides prognostic information regarding mortality or disease recurrence and is expected to improve risk stratification of coronary artery disease (CAD) beyond clinical risk factors (6789).

In evaluating diagnostic imaging tests, patient health outcomes can measure higher levels of efficacy than diagnostic accuracy (10). Radiologic imaging techniques are being developed for accurate detection and early diagnosis, which will eventually affect patient outcomes. Hence, with results attained through radiological means, especially diagnostic imaging results, being incorporated into a clinical prediction model, the predictive ability of the model may improve in both diagnostic and prognostic settings. In this review, we aim to explain conceptually the process for development and validation of a clinical prediction model involving radiological parameters with regards to the study design and statistical methods.

There are several similarities between diagnostic and prognostic prediction models (11). The type of outcome is often binary; either the disease is present or absent (in diagnosis) or the future event occurs or does not occur (in prognosis). The key interest is in generating the probability of the outcome occurring for an individual. Estimates of probabilities are rarely based on a single predictor, and combinations of multiple predictors are used; therefore, orgprediction is inherently multivariable. The same challenges and measures exist for developing and assessing the prediction model. This model can be developed for either ill or healthy individuals.

The main difference is the time at which outcomes are evaluated. In diagnosis, outcome is evaluated at the same time of prediction for individuals with a suspected disease. In prognosis, models estimate the probability of a particular outcome, such as mortality, disease recurrence, complications, or therapy response, occurring in a certain period in the future; therefore, collecting follow-up data is more important. Consequently, diagnostic modeling studies involve a cross-sectional relationship, whereas prognostic modeling studies involve a longitudinal relationship.

The performance of a statistical model depends on the study design and the quality of the analyzed data. Various study designs can be used to develop and validate a prediction model. Diagnostic accuracy studies are often designed as cross-sectional studies in which, typically, the diagnostic test results and the results of a reference test are compared to establish the ground truth regarding the presence or absence of the target disease performed for a group of subjects in a short duration. Prospective studies using a pre-specified protocol for systematic diagnostic work-up and reference standard testing in a well-defined clinical cohort, i.e., a cohort-type diagnostic accuracy study, are preferred to retrospective studies so as to minimize incomplete test results and/or assessment bias. Case-control-type accuracy studies can also be applied in prediction model studies (12). However, patient sampling for the presence or absence of the target disease and including non-consecutive patients leads to selection bias and loss of generalizability.

The best design for prognostic studies is a cohort study. Healthy or symptomatic participants are enrolled in the cohort at a certain time interval and are followed over time in anticipation of the outcome or event of interest. Such studies can be prospective or retrospective; the preferred design is a prospective longitudinal cohort study because it is efficient to optimally control and measure all predictors and outcomes and minimize the number of missing values and those lost to follow-up. Alternatively, retrospective cohort studies are often performed with existing databases such as hospital records systems or registries. In these cases, it is possible to have longer follow-up times, and obtaining records incurs a relatively lower cost than in the prospective design. However, some information is often missing or incorrect, leading to a selection bias.

Randomized clinical trials are a subtype of the prospective cohort design, and thus can also be used for prognostic models. However, the main disadvantages may be in the selection of patients. Participants are enrolled strictly according to inclusion/exclusion criteria and receipt of informed consent, decreasing the generalizability of this model.

Candidate predictors include patient demographics, disease type and severity, history characteristics, physical examination, biomarkers, and tests results. Predictors should be reliably measured and well defined by any observer. Inter-observer variability caused by subjective interpretation is a specific concern when imaging test results are involved as predictors. Predictor assessors should always be blinded to the outcome and vice versa, particularly if the predictors involve subjective interpretation of an imaging test or pathology results, in order to prevent potential bias in estimation of the association between predictors and outcome.

The outcomes of a prediction model are preferably focused on patient-relevant outcomes. In diagnostic modeling, the outcome is the presence or absence of a specific target disease state (i.e., reference standard information) at the time of the diagnostic test. For prognostic models, common outcomes relate to mortality (e.g., all-cause or cause-specific), non-fatal events (e.g., disease progression, tumor growth, and cardiovascular events), and patient-centered outcomes (e.g., symptoms, and health-related quality of life).

The measures of association are not directly linked to a predictor's ability to classify a participant (23). In other words, the prediction models are focused on absolute risks, not on relative risks such as odds ratios or hazard ratios. To evaluate the strength of the predictions from the model, measures of performance (not of association) are needed.

Traditional overall performance measures can be quantified by the distance between the predicted and actual outcome. The coefficient of determination (denoted as R2 in linear regression models) of the percentage of total variance of outcomes explained by the prediction model is used for continuous outcomes. For binary or time-to-event outcomes, the newly proposed R² or Brier score can be used to present overall performance measures (242526). However, the common types of outcome in the prediction model in medicine are the binary or time-to-event outcomes, and in such cases, the most important aspects of model performance can be assessed in terms of calibration and discrimination.

The purpose of a prediction model is to provide valid prognoses for new patients; hence, validation is an important aspect of the predictive modeling process. Internal validation is a necessary part of model development. It determines the reproducibility of a developed prediction model for the derivative sample; and prevents over-interpretation of current data. Resampling techniques such as cross-validation and bootstrapping can be performed; bootstrap validation, in particular, appears most attractive for obtaining stable optimism-corrected estimates (1). The optimism is the decrease between model performance (e.g., c-index) in the bootstrap sample and in the original sample, which can adjust the developed model for over-fitting. To obtain these estimates, we first develop the prediction model in the development cohort (n = 960 in our example), and then generate a bootstrap sample by sampling n individuals with replacement from the original sample. After generating at least 100 bootstrap samples, the optimism-corrected model performance can be obtained by subtracting the estimated mean of the optimism estimate value from the c-index in the original sample. In our example study, with 500 bootstrap replications, the estimated optimism is 0.005, and the optimism-corrected c-index of 0.796 (= 0.801 - 0.005) showed good discrimination. In addition, statistical shrinkage techniques for adjusting regression coefficients can be used to recalibrate the model (1).

Another aspect is external validity. External validation is essential to support generalizability (i.e., general applicability) of a prediction model for patients other than those in the derivative cohort. External validation can be achieved by evaluating the model performance (e.g., c-index) in data other than that used for the model development. Therefore, it is performed after developing a prediction model. There are several types of external validation, such as validation in more recent patients (temporal validation), in other places (geographic validation), or by other investigators at other sites (fully independent validation). Formal sample size calculations based on statistical power considerations are not well investigated for external validation studies. However, a substantial sample size is required to validate the prediction model to achieve adequate model performance in the validation set. The number of events and predictors has an effect in determining the sample size for external validation data for the development of the prediction model. Simulation studies suggested that a minimum of 100 events and/or 100 non-events is required for external validation of the prediction model (3637), and a systematic review found that small external validation studies are unreliable and inaccurate (38). In our example study, we had a new dataset including 236 patients from another hospital in January–June 2013. External validation using these data showed that our model (new model) discriminates well (c-index = 0.893, 95% CI, 0.816–0.969).

To compare different prediction models, the improvement in discrimination can be assessed by quantifying an incremental value such as the change in the c-index. The statistical significance of the difference between the two models can be tested by the method used by DeLong et al. (39), which was designed to compare two correlated ROC curves. In our example, the c-index values were 0.748 (95% CI, 0.696–0.800) for the old model, and 0.801 (95% CI, 0.749–0.852) for the new model, and the difference of 0.053 (95% CI, 0.021–0.085) between the two models was statistically significant (p = 0.001). It can be interpreted that discriminatory ability improved significantly when CCTA finding (significant CAD) was added to the old model. Figure 2 illustrates ROC curves for the two models.

However, when the new predictor(s) adds to an existing clinical prediction model as in our example, the c-index is often conservative in model comparisons (40). A simulation study showed that statistical testing on the difference of the AUC (c-index), such as the method from DeLong et al. (39), is not recommended when the test of the added predictor is not significant (41). Ware (42) showed that the measure of association between the risk factor and predicted outcome (e.g., odds ratio or hazard ratio) does not reflect the predictive (discriminative) ability. Thus, very large associations are required to significantly increase the prognostic performance.

To overcome these drawbacks, Pencina et al. (43) proposed two indexes–net reclassification improvement (NRI) and integrated discrimination improvement (IDI)–to quantify the amount of overall reclassification and to evaluate the incremental value of predictors. These were originally proposed for comparing nested models, but they can also be used for comparing two non-nested models.

The NRI is the net proportion of events reclassified correctly plus the net proportion of nonevents reclassified correctly, for a pre-specified set of cut-off points. If D denotes the disease status, the NRI is defined as where an upward movement (up) refers to a change of the predicted risk into a higher category based on the new model and a downward movement (down) refers to a change in the opposite direction. Thus, the NRI is an index that combines four proportions and can have a range from -2 to 2. The above NRI has two components–event NRI and non-event NRI–the net percentage of persons with (without) the event of interest correctly classified upward (downward). In our example, we measured the incremental prognostic value of the CCTA finding by calculating the NRI and the IDI. We chose risk categories based on frequently used cut-off values in the cardiovascular disease field corresponding to 10% to 20% (7). The results regarding reclassification by the model with or without CCTA finding including calculation details, are shown in Table 3. The categorical NRI was 0.266 (95% CI, 0.131–0.400), with 24.0% and 2.6% of patients who died and survived, respectively, correctly reclassified by the model with CCTA finding added. As the weights for event and nonevent groups are equal in the overall NRI, this may be problematic in cases of low disease occurrence. Therefore, it is recommended that authors report separately both the event and non-event components of the NRI separately, along with the overall NRI (444546).

Category-based NRI is highly sensitive to the number of categories, and higher numbers of categories lead to increased movement of subjects, thus inflating the NRI value. In several diseases, there are no established risk categories, and the selection of thresholds defining the risk categories can influence the NRI amount. In this situation, two or more NRIs can be employed according to the different risk categories (47). Additionally, the continuous (category-free) NRI suggested by Pencina et al. (48) was presented, which considers any change (increase or decrease) in predicted risk for each individual, and it is not affected by the category cut-off. Presenting p values from statistical testing for NRI significance is discouraged because it has been proved mathematically that it is equivalent to the testing for adjusted effects of a newly added factor controlling for existing factors; instead, only confidence intervals for the NRI should be provided (454950).

The IDI is the difference in predicted probabilities between in those who do and do not have the outcome. It estimates the magnitude of the probability improvements or worsening between two models (nested or not) over all possible probability thresholds. The IDI can be interpreted as equivalent to the difference in mean predicted probability in subjects without and with the outcome. Thus, the estimation of IDI can be expressed as follows: where p̂_{new, events} is the mean predicted probabilities of an event in the new model for event group, p̂_{old, events} is the corresponding quantity in the old model, p̂_{new, nonevents} is the mean predicted probabilities of a non-event in the new model for nonevent group and p̂_{old, nonevents} is the corresponding quantity based on the old model. Although statistical testing regarding IDI was proposed by the original authors (43), other investigators demonstrated that the p value for the IDI may be not be valid even in large samples (51). Therefore, the bootstrap confidence interval for the IDI would be more appropriate. In our example, the estimated IDI was 0.057 (= 0.051 - [-0.005], 95% CI, 0.043–0.071).

Several statisticians have concluded that increases in AUC, IDI, and NRI offer complementary information. They therefore recommend reporting all three values together as measures that characterize the performance of the final model (52).

Prediction models can be used for diagnostic or prognostic purposes. Such models will be more generalizable when the properties including range or usability of predictors and outcome in the new population for application are similar to those seen in the development population. In the previous example study, the developed prediction model was designed primarily for use with elderly patients, so this model cannot be generalized to young or middle-aged adults. Rapidly changing predictors–for example, continuing developments in diagnostic tests or imaging modalities in radiology–can limit the application of the developed prediction model.

Various prediction models have been published with or without validation results. In cases where a researcher applied such an existing model to their own data, the model performance using the data was often revealed to be poor, indicating that the published prediction model requires "updating". For example, re-calibration and re-estimation of some regression coefficients including new predictors can be performed (56).

Optimal study design and statistical methods have been simultaneously developed. However, these cannot remedy any limitations in the collection of raw data and/or missing or misclassified information. Therefore, the quality of the raw data is emphasized. Efforts should be made to minimize missing values, especially required patient characteristics and/or follow-up information.

To overcome small sample size and reduced generalizability in a single-center study, individual participant data sharing in multicenter collaborative studies or "big data" from national or worldwide surveys or registries are being used to derive and/or validate the prediction model.

Reporting guidelines for various study types including randomized trial or observational studies have been published. Radiology researchers may be familiar with the standards for the reporting of diagnostic accuracy studies (STARD) statement (57). Recently, an international group of prediction model researchers developed the reporting guidelines for prediction models–transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) statement (11). In addition to the TRIPOD statements, an accompanying explanation and elaboration document with more than 500 references from statistics, epidemiology, and clinical decision-making are also available (58). Each checklist item of the TRIPOD is explained, and corresponding examples of good reporting from published articles are provided.

·Diagnostic imaging results are often combined with other clinical factors to improve the predictive ability of a clinical prediction model in both diagnostic and prognostic settings.

·The model-based prediction is inherently multivariable; and, therefore, the most frequently used approach is multivariable regression modeling.

·Predictors should be selected using both clinical knowledge and statistical reasoning.

·The model performance should be evaluated in terms of both calibration and discrimination.

·The validation, especially external validation, is an important aspect of establishing a predictive model.

·Performance of different predictive models can be compared using c-index, NRI, and IDI.

·A predictive model may be presented in the form of a regression equation or can be converted into a scoring system for an easier use in practice.